Latest Breaking News On - Canada biosimilars fact sheet - Page 1 : vimarsana.com

Sandoz Canada supports Ontario policy change to cover biosimilars which will generate significant cost savings and improve patient access to quality medicines

Sandoz Canada supports Ontario policy change to cover biosimilars which will generate significant cost savings and improve patient access to quality medicines
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

Northwest territoriesUnited kingdomJim keonKarine matteauMichel robidouxHealth canada fact sheet on biosimilarsBiosimilar patient support programHealth canada biosimilars fact sheetSandoz international gmbHealth canadaBritish columbiaNew brunswickNova scotiaOntario governmentGeneral managerSandoz canada

Sandoz Canada congratulates the Quebec government on

French The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a biosimilar. This will contribute to substantial annual savings that can be reinvested in healthcare and innovative new drugs. The transition will take place under the supervision of the attending physicians and patients will continue receiving safe and effective treatment. Sandoz Canada has a portfolio of six biosimilars (Omnitrope, Rixymio, Erelzi, Hyrimoz, Ziextenzo and Inclunox). Sandoz Canada is committed to supporting patients, their healthcare professionals and the Quebec government throughout the transition period with quality biosimilar medicines, medical teams, physician and pharmacist advocacy teams, as well as proven patient support programs.

United kingdomKarine matteauPaule pelletierMichel robidouxSandoz canada incHealth canada biosimilars fact sheetSandoz international gmbHealth canadaBritish columbiaNew brunswickQuebec governmentSandoz canadaGeneral managerVice presidentPatented medicines pricing review boardInternational gmbh

New biosimilar switch policy in New Brunswick improves patient access to safe and effective medicines

Article content New Brunswick joins British Columbia and Alberta in implementing “switch” policy that changes coverage for specific biologic medicines. Patients switching from reference biologics to biosimilar versions will continue receiving safe, effective treatment while saving millions of dollars every year. Sandoz Canada is committed to supporting patients, their healthcare professionals, and the New Brunswick Government with high quality biosimilar medicines and experienced, comprehensive patient support programs. BOUCHERVILLE, Quebec, April 21, 2021 (GLOBE NEWSWIRE) Sandoz Canada, a leader in generic pharmaceuticals and biosimilars, welcomes the New Brunswick Government introduction of a biosimilars switch policy to expand access to high-quality biologic medicines so that patients can benefit from these treatments.

United kingdomSandoz gmbKarine matteauPaule pelletierMichel robidouxSandoz canada incHealth canada biosimilars fact sheetSandoz international gmbHealth canadaNew brunswickBritish columbiaNew brunswick governmentSandoz canadaGeneral managerVice presidentHead biosimilars

Sandoz Canada receives authorization from Health Canada to launch new biosimilar Hyrimoz® (adalimumab) - Press Release

Hyrimoz approved for use in all same indications as reference medicine including rheumatology, gastroenterology and dermatology. Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. BOUCHERVILLE, Quebec, Dec. 17, 2020 (GLOBE NEWSWIRE) Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®) on November 4, 2020 for marketing in Canada. Hyrimoz ® has been approved for the treatment of the same nine (9) life-threatening or serious debilitating conditions in adults and children as the reference medicine , including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.

Karine matteauPaule pelletierMichel robidouxOntario drug policy research networkSandoz international gmbSandoz canada incExchange commissionHealth canada biosimilars fact sheetHealth canadaAbbvie biotechnology incVice presidentHead biosimilarsGeneral managerPatented medicines pricing review boardInternational gmbhSandoz canada